The precision neuroscience company is working on treatment of anxiety disorders and depression. : Mumbai: Medicine for anxiety and depression without any of the known side effects of the currently available therapies—that's the promise upon which Engrail Therapeutics has raised $157 million of venture capital in a funding round that saw significant oversubscription from investors. The precision neuroscience company, co-founded by former Cipla executive Vikram Sudarsan, will now invest the capital to support its product pipeline for neuropsychiatric and neurodevelopmental disorders.